GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...

(Alliance News) - GSK on Tuesday said its urinary tract infection treatment gepotidacin, under the brand name Blujepa, has been approved in the US.

For much of her early career, Shobie Ramakrishnan called Silicon Valley home. GSK’s chief digital and technology officer ...

UK pharma major GSK (LSE: GSK) today announced a major new research collaboration with the UK Dementia Research Institute (UK ...

As of December 31, 2024, AnaptysBio had cash, cash equivalents, and investments greater than $420 million and anticipates ...

Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or ...

Farther Finance Advisors LLC decreased its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 27.4% during the fourth ...

GSK plc (LON:GSK – Get Free Report)’s share price passed above its two hundred day moving average during trading on Thursday ...

GSK’s chief commercial officer Luke Miels said the company expects its vaccine sales to decrease this year in part due to ...

GSK has three segments: Specialty Medicines (HIV, Oncology, Immunology/Respiratory and Other), Vaccines (Meningitis, Influenza, Shingles, RSV and Established Vaccines) and General Medicines ...